BrainStorm Cell Therapeutics Inc. (BCLI) stock
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $8.50M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.52M
- EPS, diluted
- -$0.95
- Book value per share
- -$1.05
- Diluted shares
- 11M
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $0.78
- Open
- $0.83
- Day's range
- $0.77 – $0.83
- Volume
- 6,848
- Average volume (20 days)
- 9,998
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BCLI | S&P 500 | Difference | BCLI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.4% | +0.6% | −15.1 pts | ||
| 3 months | -14.1% | +3.4% | −17.5 pts | ||
| Year to date | +39.2% | +13.3% | +26.0 pts | ||
| 1 year | +18.5% | +16.6% | +1.9 pts | ||
| 3 years | -74.3% | +86.4% | −160.7 pts | -36.4% | +23.1% |
| 5 years | -98.4% | +81.9% | −180.2 pts | -56.1% | +12.7% |
| 10 years | -97.8% | +318.9% | −416.6 pts | -31.7% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BrainStorm Cell Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
About BrainStorm Cell Therapeutics
Biological Products, (No Diagnostic Substances)
Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous cellular therapies for neurodegenerative conditions. Its core technology platform, NurOwn, processes a patient's own bone marrow-derived mesenchymal stem cells to produce neurotrophic factors that promote nerve cell survival and reduce neuroinflammation. The company primarily directs its investigational therapies toward neurodegenerative diseases such as amyotrophic lateral sclerosis, progressive multiple sclerosis, and Alzheimer's disease. Its treatments target patients suffering from these central nervous system disorders.
Company profile, executives and historyBrainStorm Cell Therapeutics stock: common questions
What is BrainStorm Cell Therapeutics's stock price?
BCLI closed at $0.77 on Oct 19, 2026, down 1.17% on the day.
What is BrainStorm Cell Therapeutics's market cap?
BrainStorm Cell Therapeutics was worth $8.50M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BCLI's P/E ratio?
BrainStorm Cell Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.95), so it has no meaningful P/E ratio.
Does BrainStorm Cell Therapeutics pay a dividend?
No. BrainStorm Cell Therapeutics has not paid a cash dividend over the last twelve months.
When does BrainStorm Cell Therapeutics report earnings next?
BrainStorm Cell Therapeutics is expected to report Q3 FY2026 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has BCLI stock performed over the past year?
Including dividends, BCLI returned +18.5% over the past year, against +16.6% for the S&P 500.
Who are BrainStorm Cell Therapeutics's competitors?
Companies most similar to BrainStorm Cell Therapeutics by business, industry and size include LCTX, INMB, BIIB, MESO, IPSC.
See a number that looks wrong?